[Sorafenib in advanced hepatocellular carcinoma].
Sauerbruch
T
T
Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Deutschland. Tilman.Sauerbruch@ukb.uni-bonn.de
Gonzalez-Carmona
A M
AM
Nitschmann
S
S
D000368:Aged; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D048490:raf Kinases / Q000037:antagonists & inhibitors*
D001557:Benzenesulfonates; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D048490:raf Kinases